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Abstract The role of anti-epithelial growth factor receptor
monoclonal antibodies (anti-EGFR MoAbs) in treatment-
related electrolyte disorders is still controversial. Therefore,
we conducted a meta-analysis of published randomized con-
trolled trials (RCTs) to evaluate the incidences and overall
risks of all-grade and grade 3/4 electrolyte disorder events. We
searched relevant clinical trials from PubMed, EMBASE, and
Web of Knowledge databases, meeting proceedings of
American Society of Clinical Oncology and the European
Society of Medical Oncology, as well as ClinicalTrials.gov.
Eligible studies included phases II, III, and IV RCTs.
Statistical analysis was performed to calculate the summary
incidence, relative risk (RR), and 95 % confidence intervals
(CIs) using fixed effects or random effects models based on
the heterogeneity of included studies. A total of 16,411 pa-
tients from 25 RCTs were included in this meta-analysis. The
all-grade incidence of hypomagnesemia related to anti-EGFR
MoAbs was 34.0 % (95 % CI 28.0–40.5 %), and that for
hypokalemia and hypocalcemia were 14.5 % (95 % CI 8.2–
24.4 %) and 16.8 % (95 % CI 14.2–19.7 %), respectively.
Compared with chemotherapy alone in colorectal cancer,
addition of cetuximab increased the risk of grade 3/4 hypo-
magnesemia and grade 3/4 hypokalemia with RRs of 7.14
(95 %CI 3.13–16.27, p<0.001) and 2.19 (95 %CI 1.14–4.23,
p=0.019). Additionally, colorectal cancer patients in
panitumumab cases were more vulnerable to grade 3/4 hypo-
magnesemia and hypokalemia (RR 18.29, 95 % CI 7.29–
48.41, p<0.001, and RR 3.3, 95 % CI 1.32–8.25, p=0.011).
Treatment with anti-EGFR MoAbs is associated with signif-
icantly higher risks of electrolyte disorders such as hypomag-
nesemia, hypomagnesemia, and hypocalcemia, especially in
colorectal cancer. Rigorous monitoring and early treatment of
electrolyte disorders are proposed.
Keywords Electrolyte disorders . Cetuximab .
Panitumumab .Meta-analysis
Introduction
Epithelial growth factor receptor (EGFR), which is also
known as erbB1 or HER1, is the first growth factor receptor
to be proposed as a target for anti-cancer therapy [1]. EGFR is
a 170-kDa transmembrane protein with an intracellular tyro-
sine-kinase, which can be overexpressed by a range of differ-
ent tumors such as colorectal cancer, head and neck cancer,
lung cancer, pancreas cancer, and breast cancer [2]. It is crucial
in modulating cellular signaling pathways including prolifer-
ation, inhibition of apoptosis, angiogenesis, invasion, and
metastasis, making it a promising target for anti-cancer agent
[3]. At present, anti-EGFR agents mainly include two types:
tyrosine-kinase inhibitors (TKI) and monoclonal antibodies
(MoAbs) [4]. TheMoAbs approved by the US Food and Drug
Administration (FDA) include cetuximab (Erbitux™), a chi-
meric immunoglobulin G1 antibody, in February 2004 and
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panitumumab (Vectibix™), a fully-human immunoglobulin
G2 antibody, in September 2006 [5, 6]. These agents are still
being evaluated in treatment of various advanced malignant
diseases such as colorectal cancer, non-small-cell lung cancer
(NSCLC), head and neck cancer, and so on. Thus, more
applications of MoAbs are expected in the near future.
With respect to side effects, the most specific and frequent-
ly toxic effect of anti-EGFR MoAbs is acneiform eruption,
skin rash, and other cutaneous events. They have been
regarded as typical class adverse events related to MoAbs
[7]. However, electrolyte disorders are also common adverse
events during anticancer therapy but are often overlooked. If
decreased electrolytes have not been managed timely, fetal
events like cardiac arrhythmia, coronary artery vasospasm,
and sudden cardiac death might take place. What is more, on
account of lacking monitoring system, it would be more
dangerous in outpatients.
Since the indications for anti-EGFRMoAbs are increasing,
it is prerequisite to recognize the patterns of toxic effects such
as incidence and relative risk (RR) of electrolyte disorder
events and to understand the mechanism of the drug, so that
early and essential intervention can be done. To our knowl-
edge, on account of the limited number of patients in trials,
there is no clinical trial with a great capacity to explore
electrolyte disorders associated with MoAbs agents in detail.
Thus, in order to better understand the overall risk of electro-
lyte disorders, we conducted a meta-analysis of published
randomized controlled trials (RCTs) to investigate the inci-
dence and RR of all-grade and grade 3/4 electrolyte disorders




This study was performed in accordance with Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement [8]. The first two authors independently
conducted a comprehensive literature search of PubMed
(January 1, 1966 to June 30, 2014) using the following key-
words: “panitumumab,” “Vectibix,” “ABX-EGF” or
“cetuximab,” “Erbitux,” “C-255,” limited by “clinical trial.”
Then, we manually searched bibliographies of included trials
with keywords of “randomized controlled trial” and “adverse
events.” The same keywords were used to search abstracts and
virtual meeting presentations from the American Society of
Clinical Oncology (ASCO) and the European Society of
Medical Oncology (ESMO) conferences. Information on on-
going registered clinical trials from the National Institutes of
Health Web site (http://www.clinicaltrials.gov) was also
referenced. The search strategy was also carried out to
search the database EMBASE and Web of Knowledge to
make sure that no relevant trials were neglected. Only the
most recent, complete and full manuscripts from clinical trials
were included.
Eligibility criteria
The principal objective of this study was to determine the
incidence and the overall risk of electrolyte disorders associ-
ated with anti-EGFR MoAbs. Thus, trials that matched the
following criteria were included: (1) participating patients
with all solid tumors at baseline; (2) randomized controlled
phases II, III, and IV clinical trials; (3) patients were assigned
to cetuximab or panitumumab therapy and controls; and (4)
data available for the events of electrolyte disorders and
sample size for analysis. We excluded studies if they met the
following criteria: (1) phase I trials or single arm phase II trials
that lack of controls; (2) any meta-analysis, comment, review,
and case report; (3) retrospective trials; and (4) trials lack of
suitable data of electrolyte disorders.
Data extraction and study quality assessment
Two authors independently reviewed the full studies and the
following information were included into an electronic data-
base: name of first author, year of publication, trial phase,
number of patients enrolled and analyzed, patients status,
follow-up duration, underlying malignancy, treatment
methods, National Cancer Institute’s Common Terminology
Criteria for Adverse Events (CTCAE) criteria version, and
adverse outcomes of events interest (hypomagnesemia, hypo-
kalemia, hypocalcemia, and hyponatremia). We included the
exact number of patients who occurred adverse events interest
of all-grade and grade 3/4 and number of total patients en-
rolled in the clinical trials. The study quality was assessed by
the same two reviewers independently according to the Jadad
score which included randomization, blinding, and with-
drawals, ranging from 0 to 5 points [9]. Any discrepancies
were resolved by joint review of the manuscript to reach
consensus.
Statistical analysis
We used Comprehensive Meta Analysis program version 2
(Biostat, Engle-wood, NJ, USA) to pool data. The incidence,
RR, and their 95 % confidence intervals (CIs) of adverse
events were calculated for each study, and the results were
compared through both random effects model (Der-Simonian
and Laird’s method [10]) and fixed effects model (Mantel-
Haenszel method). Statistical heterogeneity among studies
was assessed by Cochrane’s Q statistic and I2 statistic [11].
The I2 value provides an estimate of amount of variance across
studies derived from heterogeneity rather than chance. If p
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value of Cochrane’s Q statistic <0.1, the assumption of homo-
geneity was deemed invalid and a random effects model was
reported; otherwise, results from the fixed effect model were
reported. RR >1 reflects a higher overall risk of adverse
events. All p values were two-tailed and were considered
statistically significant if p<0.05.
Subgroup analysis was performed by tumor type and
MoAbs agent category. Sensitivity analysis was based on the
weight or quality of the studies to assess the robustness of
primary results. Publication bias was evaluated using Begg’s
and Egger’s tests [12, 13].
Results
Literature search results
Seven hundred eighty-four potentially relevant clinical trials
with anti-EGFR MoAbs were identified with the search strat-
egy, of which 145 were initially excluded as duplicates
(Fig. 1). After a review of the titles and abstracts of the
remaining 639 publications, 172 trials were judged as prom-
ising articles. These articles were selected and evaluated in
greater detail by reviewing the full articles. And, finally, 25
RCTs were considered as highly relevant trials for the meta-
analysis.
Study characteristics
Twenty-five RCTs reporting 23,094 patients were identified,
among which, 16,411 were actually exposed to the original
study. There were 3011 total electrolyte disorder events
among these patients (anti-EGFR MoAbs, n=2161; controls,
n=850). Table 1 shows the baseline characteristics of each
trial. Underlying malignancies included colorectal cancer (11
studies) [14–24], NSCLC (five studies) [25–29], head and
neck cancer (three studies) [30–32], oesophageal cancer (three
studies) [33–35], pancreatic cancer (one study) [36], gastric
cancer (one study) [37], and breast cancer (one study) [38].
National Cancer Institute’s Common Terminology Criteria for
Adverse Events (CTCAE) criteria, version 2, 3, or 4 were used
to evaluate the adverse events in these studies. The differences
between the three versions were presented in Supporting
Information Table 1 (Online Resource). These trials include
4 phase II [18, 26, 27, 38], 18 phase III [14–17, 19, 21–25,
28–32, 34, 36, 37], and 2 phase II/III studies [33, 35], and one
study did not report the exact phase [20]. Thirteen studies
mentioned follow-up duration, and 21 reported hypomagne-
semia events, 16 studies for hypokalemia events, four for
Fig. 1 The literature search
process
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hypocalcemia events, and three for hyponatremia events as
shown in Table 1. In all trials, patients were randomly assigned
to with or without MoAbs-treated groups, according to Eastern
Cooperative Oncology Group performance status or other
criteria. Patients enrolled in the MoAbs group received
cetuximab 400 mg/m2 at first dose and 250 mg/m2 per week
(or 500 mg/m2 every 2 weeks) or panitumumab 6 mg/kg (or
9 mg/kg according to the tumor types) on day 1 of each cycle.
The overall methodological study quality was generally good
and fair with a Jadad mean score of 3.04, ranging from 2 to 5.
Incidence of electrolyte disorder events
Incidence of hypomagnesemia events
Twenty RCTs reported grade 3/4, and ten reported all-grade
hypomagnesemia events. All-grade hypomagnesemia events
were recorded in 879 of 2682 patients in MoAbs-treated
group, conferring an incidence of 34.0 % (95 % CI 28.0–
40.5 %), whereas that in controls was 9.7 % (95 % CI 6.5–
14.3 %) (Table 2), indicating a higher risk of all-grade hypo-
magnesemia events related to MoAbs (RR 3.37, 95 % CI
2.41–4.72, p<0.001) (Online Resource Fig. 1). The incidence
of grade 3/4 hypomagnesemia events in MoAbs was also
significantly higher than control group (incidence 4.8 %,
95 % CI 3.6–6.4 %, vs 0.7 %, 95 % CI 0.4–1.2 %,
p<0.001), with RR value of 6.10 (95 % CI 4.37–8.52,
p<0.001) (Fig. 2).
Incidence of hypomagnesemia events was then calculated
for cetuximab and panitumumab trials separately (Table 2). Of
note, among cetuximab trials, incidences of all-grade and
grade 3/4 hypomagnesemia events in cetuximab group were
approximately three times (incidence 34.9 %, 95 % CI 25.9–
45.1 %, vs 12.6 %, 95 % CI 9.0–17.3 %) and 5.5 times
(incidence 4.4 %, 95 % CI 2.9–6.7 %, vs 0.8 %, 95 % CI
0.6–1.3 %) higher than in controls (p<0.001 for both)
(Table 2). In panitumumab trials, the effects of hypomagne-
semia events were also obvious, all-grade incidence of
panitumumab group and control group: 31.8 %, 95 % CI
27.9–36.0 %, vs 3.8 %, 95 % CI 0.7–17.0 %; grade 3/4
incidence 5.4 %, 95 % CI 3.5–8.3 %, vs 0.4 %, 95 % CI
0.1–1.9 % (Table 2). Then, the trials included were stratified
for underlying malignant disease. The incidence of grade 3/4
hypomagnesemia events related to cetuximab in colorectal
cancer trials was 2.9 % (95 % CI 1.7–4.7 %) [14–20]. While
the incidence in panitumumab group was higher with 4.6 %
(95 % CI 3.5–6.1 %) (Table 2) [21–24].
Incidence of hypokalemia events
Sixteen RCTs reported grade 3/4 and six RCTs reported all-
grade hypokalemia events. The grade 3/4 events of anti-EGFR
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incidence of 6.7 % (95 % CI 5.2–8.7 %), whereas in the
control group, the incidence was 3.7 % (95 % CI 2.5–5.4 %)
(Online Resource Table 2), implying that addition of anti-
EGFR MoAbs increased the risk of hypokalemia (RR=1.68,
95 % CI 1.40–2.03; p<0.001) (Fig. 2). Similarly, incidence of
all-grade hypokalemia inMoAbs group (14.5%, 95%CI 8.2–
24.4%) was higher than controls (9.7%, 95%CI 6.0–15.2%,
p<0.001) (Online Resource Table 2).
All-grade hypokalemia events with cetuximab occurred in
12.6 % patients and grade 3/4 incidence was 6.1 %, both of
which were significantly higher than their controls (p<0.001
for both) (Online Resource Table 2). In subanalysis of differ-
ent tumor types, the addition of cetuximab augmented notably
the incidence of grade 3/4 events in colorectal cancer (2.7,
95 % CI 0.8–8.3) and NSCLC (5.7, 95 % CI 2.9–10.9). For
panitumumab treatment group, colorectal cancer patients re-
ceived an obviously higher incidence of grade 3/4 events than
those in controls (7.2 vs 2.1 %, p<0.001).
Incidence of hypocalcemia or hyponatremia events
Four RCTs recorded grade 3/4 and two RCTs recorded all-
grade hypocalcemia events. The incidence of all-grade
hypocalcemia related to cetuximab was 16.8 % (95 % CI
14.2–19.7 %), while the control was 9.9 % (95 % CI 8.0–
12.2 %). And, grade 3/4 hypocalcemia of cetuximab and
panitumumab was 3.8 % compared with 2.0 % (Online
Resource Table 3).
Three RCTs noted grade 3/4, and one noted all-grade
hyponatremia events associated with anti-EGFRMoAbs treat-
ment (all of them were in cetuximab trials). The overall
incidence of grade 3/4 and all-grade events was 7.8 % (95 %
CI 2.1–25.0%) and 9.4 % (95%CI 7.0–12.5%), respectively.
However, no significant difference was found (p>0.05 for
both) (Online Resource Table 4).
Relative risk of grade 3/4 electrolyte disorder events
Relative risk of grade 3/4 hypomagnesemia events
As an exploratory analysis, patients were stratified according
to anti-EGFR MoAbs (cetuximab or panitumumab) and un-
derlying malignant disease. Studies of cetuximab showed that
14 RCTs were available to calculate the RR of grade 3/4
hypomagnesemia events. Events treated with or without
cetuximab were 168/3798 and 21/3606 (RR 6.23, 95 % CI
Table 2 Incidence of grade 3/4 or all-grade hypomagnesemia events with MoAbs according to tumor types and MoAbs agents
Groups No. No. of grade 3/4 events/total no. Incidence (95 % CI)a p value
MoAbs Control MoAbs Control
Grade 3/4
Cetuximab Overall 14 168/3798 21/3606 4.4 (2.9–6.7) 0.8 (0.6–1.3) <0.001
Colorectal cancer 6 56/2151 5/2036 2.9 (1.7–4.7) 0.4 (0.2–0.8) <0.001
NSCLC 3 33/681 4/675 3.7 (1.2–11.1) 0.7 (0.3–1.8) <0.001
Head and neck cancer 2 19/277 3/273 8.3 (3.0–21.0) 1.3 (0.5–3.6) 0.001
Esophageal cancer 1 9/129 2/129 7.0 (3.7–12.9) 1.6 (0.4–6.0) 0.031
Gastric cancer 1 47/446 6/436 10.5 (8.0–13.7) 1.4 (0.6–3.0) <0.001
Breast cancer 1 4/114 1/57 3.5 (1.3–9.0) 1.8 (0.2–11.4) 0.521
Panitumumab Overall 6 138/2426 16/2420 5.4 (3.5–8.3) 0.4 (0.1–1.9) <0.001
Colorectal cancer 4 85/1825 4/1829 4.6 (3.5–6.1) 0.3 (0.1–0.6) <0.001
Esophageal cancer 1 13/276 0/266 4.7 (2.8–7.9) 0.2 (0.0–2.9) <0.001
Head and neck cancer 1 40/325 12/325 12.3 (9.2–16.3) 3.7 (2.1–6.4) <0.001
Overall 20 306/6224 37/6026 4.8 (3.6–6.4) 0.7 (0.4–1.2) <0.001
All-grade
Cetuximab Overall 7 559/1659 188/1545 34.9 (25.9–45.1) 12.6 (9.0–17.3) <0.001
Colorectal cancer 4 329/857 91/754 35.8 (24.3–49.1) 12.0 (9.0–16.0) <0.001
NSCLC 2 97/356 36/355 37.0 (10.3–75.1) 13.7 (2.5–49.7) <0.001
Gastric cancer 1 133/446 61/436 29.8 (25.8–34.2) 14.0 (11.0–17.6) <0.001
Panitumumab Overall 3 320/1023 57/1010 31.8 (27.9–36.0) 3.8 (0.7–17.0) <0.001
Colorectal cancer 2 231/747 16/744 31.9 (25.4–39.1) 1.8 (0.6–5.4) <0.001
Esophageal cancer 1 89/276 41/266 32.2 (27.0–38.0) 15.4 (11.6–20.3) <0.001
Overall 10 879/2682 245/2555 34.0 (28.0–40.5) 9.7 (6.5–14.3) <0.001
MoAbs monoclonal antibodies, CI confidence interval, NSCLC non-small-cell lung cancer
a Calculated using the random-effect model (Comprehensive Meta Analysis 2, Biostat)
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4.01–9.66, p<0.001) and the p value of Cochrane’s Q statistic
was 0.93 (I2=0), justifying the use of the fixed effect model
(Mantel–Haenszel) (Fig. 3). Six RCTs of panitumumab
contained 138 grade 3/4 hypomagnesemia events in 2426
patients compared with 16 events in 2420 patients in control
(RR 11.18, 95 % CI 4.20–29.80, p<0.001) (Fig. 3) using
random effect model. The heterogeneity existed (p=0.072,
I2=50.7 %), and sensitivity analysis was conducted. It seemed
that when we omitted the study conducted by Vermorken
et al., the heterogeneity decreased to 0 % (p=0.997), though
the result was precarious with RR of 19.42 (95 % CI 7.92–
47.63, p<0.001) (Fig. 3).
When stratifying for underlying cancers, we noted the RR
of grade 3/4 hypomagnesemia events varied either in
cetuximab trials (p<0.001) or panitumumab trials (p=0.004,
data not shown). Subanalysis showed that colorectal cancer
patients had the highest RR: 7.14 of cetuximab (95 % CI
3.13–16.27, p<0.001) and 18.79 of panitumumab (95 % CI
7.29–48.41, p<0.001) (Fig. 3). Significant statistical
differences were also observed in NSCLC (RR=7.02, 95 %
CI 2.43–20.34, p<0.001), head and neck cancer (4.66, 95 %
CI 1.47–14.76, p=0.009) in cetuximab trials, as well as non-
colorectal cancer in panitumumab trials (3.67, 95 % CI 1.99–
6.77, p<0.001) (Fig. 3).
Relative risk of grade 3/4 hypokalemia events
Upon stratification by MoAbs agents, we observed that the
RR of grade 3/4 hypokalemia events was 1.64 (95 % CI 1.29–
2.08, p<0.001) for cetuximab-based regimens and 1.86 (95 %
CI 0.95–3.61, p=0.069) for panitumumab-based regimens
(Fig. 4). No heterogeneity was detected among ten cetuximab
trials (p=0.642, I2=0). As some trials had a wide variation in
confidence intervals in panitumumab subgroup, which could
decline the precision of pooled results, thus a sensitivity
analysis was conducted to examine the stability and reliability
of the overall RRs by sequential omission of individual stud-
ies. When the study results reported by Waddell et al. was
Fig. 2 The overall relative risk of
different grade 3/4 electrolyte
disorder events associated with
MoAbs
Tumor Biol. (2015) 36:3471–3482 3477
omitted [34], which seemed to explain the heterogeneity
among those studies, the RR value turned into 2.40 (95 %
CI 1.36–4.24) and the heterogeneity among the remaining
studies decrease to 56 % (p=0.076).
RRs of grade 3/4 hypokalemia in cetuximab trials were
significantly different between tumor types (p<0.001) but were
similar in panitumumab trials (p=0.239, data not shown).
Colorectal cancer patients presented the lower level of RR in
cetuximab-based therapy (RR=2.19, 95 % CI 1.14–4.23, p=
0.019) than in panitumumab-based therapy (RR=3.30, 95 % CI
1.32–8.25, p=0.011) (Fig. 4). And, significant statistical differ-
ence was also observed in NSCLC patients in cetuximab trials
(p=0.006). All the subgroup analysis were judged to use fixed
effect model due to the p values of Cochrane’sQ statistic of >0.1,
except those colorectal cancer patients treated with panitumumab
with the p value of 0.077 (I2=68.0 %), which was calculated
using random effect model.
Relative risk of grade 3/4 hypocalcemia or hyponatremia
events
Three RCTs reported grade 3/4 hypocalcemia related to
cetuximab, and only one RCT recorded the events with
panitumumab. Patients with cetuximab-based therapy had a
significantly higher risk of electrolyte disorders (RR=2.12,
95 % CI 1.30–3.45, p=0.003) (Online Resource Fig. 2),
whereas panitumumab did not increase this events as reported
(RR=1.14, 95 % CI 0.42–3.12, p=0.794) (Online Resource
Fig. 2).
The analysis of grade 3/4 hyponatremia events
showed that RR in cetuximab trials was 1.08 (95 %
CI 0.74–1.59, p=0.682) (Online Resource Fig. 3), but
no one reported the events of panitumumab. Due to a
lack of sufficient studies, subgroup analysis of different
tumor types was not conducted.
Publication bias
The publication bias was performed in the pooling analysis of
risk of grade 3/4 hypomagnesemia events and hypokalemia
events associated with cetuximab due to the fact that the
included studies were more than ten. Evidence of publication
bias was not detected by either Begg’s test or Egger’s test (RR
of hypomagnesemia event: Begg’s test p=0.584, Egger’s test
p=0.441, RR of hypokalemia event: Begg’s test p=0.152,
Egger’s test p=0.074, respectively)
Fig. 3 Relative risk of grade 3/4
hypomagnesemia events stratified
by tumor types and MoAbs
agents
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Discussion
Studies that investigated the toxicity of anti-EGFR MoAbs
mainly focused on the common adverse events, such as skin rash
[39], hematologic toxicity [40], and specific electrolyte distur-
bance like hypomagnesemia [41]. To our best knowledge, sel-
dom study has synthetically studied the incidence and risk of all-
grade and grade 3/4 electrolyte disorders of cetuximab- or
panitumumab-related therapy. As EGFR can be overexpressed
in a wide range of tumors and it correlates with poor survival and
cancer progression, inhibition of EGFR signaling pathway will
be a promising therapeutic target [42]. However, cetuximab and
panitumumab both bind with high affinity to human EGFR and
hence could reinforce the cytotoxic effects of conventional che-
motherapy or chemoradiotherapy [43]. Therefore, the overall
benefits of anti-EGFR MoAbs remain to be confirmed.
Electrolyte disorders are quite common in overwhelming major-
ity of cancer patients and may result in serious adverse events.
Adequate recognition andmanagement of electrolyte disorders is
important for those patients who receive anti-EGFR MoAbs
therapy. However, the relationship between grade 3/4 electrolyte
disorder events and MoAbs-based therapy is difficult to evaluate
in individual RCTs for a lack of enough patients.
In our study, data from 25 RCTs was pooled to overcome
this limitation and the results demonstrated that therapy with
anti-EGFR MoAbs can dramatically increased the risk of
grade 3/4 hypomagnesemia events (RR=6.10, 95 % CI
4.37–8,52, p<0.001; incidence compared with controls: 4.8
vs 0.7 %). And, all-grade events reached as high as 34.0 % in
MoAbs-treated group, compared with 9.7 % in controls
(p<0.001). Colorectal cancer patients had the highest risk of
grade 3/4 hypomagnesemia events among cancer patients
(cetuximab: RR=7.14; panitumumab: RR=18.79).
Meanwhile, MoAbs also obviously increased RR of grade 3/
4 hypokalemia and hypocalcemia events with the value of
1.68 and 1.88, respectively. Interestingly, colorectal cancer
patients were also more prone to have grade 3/4 hypokalemia
events than others (cetuximab: RR=2.19; panitumumab:
RR=3.30), which was similar with that of grade 3/4 hypo-
magnesemia events. However, no obviously higher risk of
hyponatremia events related to MoAbs was discovered in
our study. In brief, the risk of electrolyte disorder events was
dramatically increased if the anti-EGFR therapy was added.
Therefore, more attention should be paid to the electrolyte
disorders when patients treated with anti-EGFRMoAb agents
alone or combined with chemotherapy, whereas the mecha-
nism behind these toxicities has not yet been well identified.
Recent studies tend to suggest that a new Mg2+ permeable
channel TRPM6 (transient receptor potential cation channel,
subfamily M, member 6) and TRPM7 were involved in
Fig. 4 Relative risk of grade 3/4
hypokalemia events stratified by
tumor types and MoAbs agents
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transepithelial Mg2+ transport in the distal convoluted tubule
[44]. And, pro-EGF and TRPM6 were both predominantly
expressed in distal convoluted tubule, which was the main site
of active renal Mg2+ reabsorption. However, the stimulatory
effect of EGF on TRPM6 activity could be diminished by
preincubation of cetuximab, an EGFR blockade, thus affect-
ing Mg2+ transport and leading to hypomagnesemia [45].
Hypokalemia may relate to hypomagnesemia through
TRPM6 [46]. Increasing potassium is required to repair
Na-K-ATPase due to the magnesium deficiency. Then,
over-intracellular transport of potassium could result in
hypokalemia. Thus, on the contrary, sodium is mainly
unaltered due to the extracellular transport. Human
TRPM6 also give rise to hypomagnesemia with second-
ary hypocalcemia (HSH) [47]. Although the mechanism
responsible for development of hypocalcemia is unclear,
several explanations such as end-organ unresponsiveness
to parathyroid hormone (PTH), altered release of PTH,
and impaired formation of 1,25-dihydroxy vitamin D3
are offered. The exact pathogenesis of anti-EGFR
MoAbs associated electrolyte disorders remains to be
elucidated.
In particular, the grade 3/4 electrolyte disorders risk is
higher in colorectal cancer patients yet not the incidence,
when compared with other tumors. The differences in the
results are still unknown. However, it has to be noted that
most trials of other tumors had implemented a treatment with
cisplatin as chemotherapy, a well-known harmful agent to
renal convoluted tubules. And, it could aggravate the renal
function and result in an extensive electrolyte disorders. On
the other hand, 70–75 % colorectal cancer patients overex-
press EGFR [48], more than other cancer patients like NSCLC
with 60 % [49]. Thus, this anti-EGFR treatment might obvi-
ously raise the risks of electrolyte disorders with MoAbs as
explained previously.
To note that patients received panitumumab therapy were
more inclined to have severe electrolyte disorders than
cetuximab. The possible reason can be the absolutely high
affinity to human EGFR of panitumumab that reinforced its
adverse events [43]. Moreover, the longer half-life of
panitumumab than cetuximab (7.5 vs 4.7 days) rises the
possibility that the different pharmacokinetics of the two
MoAbs somehow matters.
For the high risk of severe hypomagnesemia events, most
studies mainly focus on the magnesium level in serum. The
RR of grade 3/4 hypomagnesemia events associated with
cetuximab reported by Petrelli et al. was 9.81 [41], higher
than 8.6 from Chen et al. [50] and 6.23 from our study. And,
the RR related with panitumumab in Petreli’s study was 11.68,
which was similar to the result of our result. The controversial
differencesmay be rooted in different qualities of clinical trials
included and some updated trials that were not included in the
previous studies.
However, despite the size of this meta-analysis, several
limitations are still worth considering. First, these studies were
conducted at major academic institutions among patients in
hospital and with adequate major organ function, which may
neglect outpatients and patients with organ dysfunction, thus
could not reflect the general patient population. Second, the
process of recording the electrolyte disorder events varies in
each clinical trial since these events were not the primary end
point of their trials. Therefore, a bias of reported incidence
rates emerges. Publication bias of risk of hypomagnesemia
and hypokalemia analysis in cetuximab setting was not de-
tected according to Begg’s and Egger’s test. However, it
should be interpreted with caution, as these methodologies
are not fully bias-free. Since the publication bias test was only
performed on the cetuximab setting which included more than
ten studies, there might be some evidences of publication bias
in the remaining analyses. Third, this is a meta-analysis at
study level, so we can not solve the confounding factors that
inherent in those included trials due to the inadequate control
and thus could result in potential bias and toward exaggeration
or underestimation of risk estimates, such as different chemo-
therapy exposures, different CTCAE versions and failure to
follow-up cases, all of which may lead to the existence of
heterogeneity in the incidence of adverse events. Finally, the
number of trials that recorded hypocalcemia and
hyponatremia events was limited. It is likely that significant
differences in hypocalcemia events between treatment arm
and controls in panitumumab trials would arise if more studies
were available. Nonetheless, all efforts have been made to
contain all related trials and all of them are well-conducted.
Majority of them are multicenter randomized phase III trials
(many are registered studies). This meta-analysis thus pooled
a limited but robust “core” of clinical data to draw a final
unequivocal result.
Conclusion
Our results indicated that incidences of electrolyte disorders
were obviously elevated with anti-EGFR MoAbs therapy,
especially in colorectal cancer patients. Addition of anti-
EGFR MoAbs would dramatically increase risk of hypomag-
nesemia events, as well as hypokalemia and hypocalcemia.
Panitumumab seemed to have a higher risk in causing severe
electrolyte disorders than cetuximab. Among different can-
cers, colorectal cancer patients receiving anti-EGFR MoAbs
treatment showed the highest risk of electrolyte disorders
compared with their controls. However, majority of patients
with electrolyte disorders are asymptomatic, although symp-
toms such as fatigue, muscular cramps, and cardiac arrhyth-
mias could be associated with electrolyte disorders. Given its
high incidence and risk, rigorous monitoring and early treat-
ment of electrolyte disorders are proposed.
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